SCHEMBL6037098

SCHEMBL6037098

C=CC(=O)NC(=O)CCC(C)=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.43
TSHR P16473 4/20 0.39
MAPK1 P28482 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
LMNA P02545 1/20 0.37
SLC15A2 Q16348 1/20 0.37
ZDHHC20 Q5W0Z9 1/20 0.34
ZDHHC2 Q9UIJ5 1/20 0.34
PSMB11 A5LHX3 1/20 0.33
PSMA7 O14818 1/20 0.33
PSMB1 P20618 1/20 0.33
PSMA1 P25786 1/20 0.33
PSMA2 P25787 1/20 0.33
PSMA3 P25788 1/20 0.33
PSMA4 P25789 1/20 0.33
PSMB8 P28062 1/20 0.33
PSMB9 P28065 1/20 0.33
PSMA5 P28066 1/20 0.33
PSMB4 P28070 1/20 0.33
PSMB6 P28072 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL853182 0.82 ALDH1A1 (0.42) ALDH1A1TSHRMAPK1TDP1LMNA
SCHEMBL2933109 0.80 HDAC3 (0.46) ALDH1A1TSHRMAPK1TDP1ZDHHC20
SCHEMBL2933508 0.77 ZDHHC20 (0.50) ALDH1A1TSHRMAPK1ZDHHC20ZDHHC2
SCHEMBL9156920 0.76 TSHR (0.50) ALDH1A1TSHRMAPK1TDP1LMNA
SCHEMBL28966764 0.76 TSHR (0.41) ALDH1A1TSHRMAPK1TDP1ZDHHC20
SCHEMBL29111068 0.75 PSMB11 (0.37) ALDH1A1TSHRMAPK1TDP1LMNA
SCHEMBL2931470 0.75 FAAH (0.55) ALDH1A1TSHRMAPK1ZDHHC20ZDHHC2
SCHEMBL19409179 0.75 MAPK1 (0.47) ALDH1A1TSHRMAPK1TDP1ZDHHC20
SCHEMBL2932979 0.75
SCHEMBL3628039 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1718341-A2 ARTICLES COMPRISING MAGNETIC MATERIAL AND BIOACTIVE AGENTS Alnis Biosciences, Inc. (US) 2006-11-08 EP disclosed
WO-2005070471-A2 ARTICLES COMPRISING MAGNETIC MATERIAL AND BIOACTIVE AGENTS ALNIS BIOSCIENCES, INC. (US) 2005-08-04 WO disclosed
US-20050129769-A1 Polymeric articles for carrying therapeutic agents ALNIS BIOSCIENCES, INC. 2005-06-16 US disclosed
EP-1531868-A2 THERAPEUTIC AGENT-CONTAINING POLYMERIC NANOARTICLES Alnis Biosciences, Inc. (US) 2005-05-25 EP disclosed
WO-2005027873-A2 THERAPEUTIC AMINOGLYCOSIDE-CONTAINING HYDROGEL NANOPARTICLES ALNIS BIOSCIENCES, INC. (US) 2005-03-31 WO disclosed
WO-2003101425-A2 THERAPEUTIC AGENT-CONTAINING POLYMERIC NANOARTICLES ALNIS BIOSCIENCES, INC. (US) 2003-12-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050129769-A1 Polymeric articles for carrying therapeutic agents CD44, EPCAM, CLTB ALDH1A1 3816/4885TSHR 1664/4885MAPK1 4417/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.